Sueyoshi, T., and Negishi, M
IM injections are the standard for rapidly restoring B12 levels, particularly in severe cases and patients with absorption issues
For BPC-157, numerous investigations in rodent models have demonstrated therapeutic benefits in wound healing, tendon repair, and gastrointestinal protection
Yes, our Sardis PA clinic successfully uses peptide therapy to promote skin rejuvenation, enhance collagen production, and support overall cellular repair, contributing to anti-aging effects
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
10.1094/PHYTO.1999.89.8.673 72 IshiharaT.SakuraiN.SekineK
